Company Overview of Clearside BioMedical, Inc.
Clearside BioMedical, Inc., a biopharmaceutical company, develops drug therapies to treat chronic blinding diseases of the eye. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
1220 Old Alpharetta Road
Alpharetta, GA 30005
Founded in 2011
Key Executives for Clearside BioMedical, Inc.
Chief Executive Officer, President and Director
Executive Vice President of Research and Development
Vice President of Research and Development
Vice President of Scientific Affairs and Member of The Scientific Advisory Board
Compensation as of Fiscal Year 2015.
Clearside BioMedical, Inc. Key Developments
Clearside Biomedical, Inc. Appoints Richard J. Croarkin to its Board of Directors
Feb 29 16
Clearside Biomedical, Inc. announced that Richard J. Croarkin has been appointed to Clearside’s Board of Directors. Mr. Croarkin is the former Senior Vice President of Finance, Chief Financial Officer & Corporate Strategy Officer of Alcon, Inc. Mr. Croarkin is currently a Director on the Board of Aerie Pharmaceuticals, Inc., which he joined in May 2015. Mr. Croarkin also serves as a panelist on the NASDAQ Listing Qualifications Panel.
Clearside Seeks Acquisitions
Jan 8 16
Clearside BioMedical, Inc., launched the initial public offering of $57.5 million, net proceeds from the issuance, in the ordinary course of our business, expect to from time to time evaluate the acquisition, investment in or in-license of complementary products, technologies or businesses, and could use a portion of the net proceeds from this offering for such activities. Clearside BioMedical currently do not have any agreements, arrangements or commitments with respect to any potential acquisition, investment or license.
Clearside Biomedical, Inc. Announces Positive Topline Data from Phase 2 Clinical Trial for the Treatment of Macular Edema Associated with Non-Infectious Uveitis
Jan 5 16
Clearside Biomedical, Inc. announced positive results from the company’s Phase 2 clinical trial of CLS-TA, Clearside’s proprietary form of triamcinolone acetonide, using suprachoroidal space (SCS™) drug administration for the treatment of macular edema associated with non-infectious uveitis. The trial, referred to as the Dogwood trial, evaluated the safety and efficacy of CLS-TA in 22 patients with macular edema associated with non-infectious uveitis. In the trial, administration of CLS-TA resulted in a statistically significant mean change from baseline in central subfield thickness at eight weeks after one single treatment, which was the primary endpoint (p=0.0018). Statistical significance was also achieved in the mean increase from baseline in best-corrected visual acuity (p=0.0004), a secondary endpoint. There were no treatment-related serious adverse events reported in the trial, including no reported steroid-related increases in intraocular pressure (IOP), which is common in intravitreal and periocular drug delivery of corticosteroids. Clearside plans on submitting the full data set for presentation at an upcoming medical meeting. The data from this clinical trial continue to provide support for the approach to treatment of certain blinding eye diseases through SCS™ administration and the potential for an effective and safe option for the treatment of uveitis using CLS-TA, Clearside’s proprietary triamcinolone acetonide formulation. The Dogwood trial was the first masked, randomized clinical trial conducted in which drug was administered through the SCS™. This U.S., multi-center trial randomly assigned patients in a 4:1 ratio to receive a single injection of CLS-TA, 4 mg/100 µL or CLS-TA, 0.8 mg/100 µL. Subjects were treated at Day 1 and were monitored for safety and efficacy for eight weeks following their SCS™ injection.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 23, 2015